产品说明
生化/生理作用
Pazopanib is an orally active receptor tyrosine kinases inhibitor against VEGFR1/2/3 (IC50 = 10/30/47 nM), PDGFR1/2 (IC50 = 84/71 nM) and c-Kit (IC50 = 74 nM), exhibiting reduced or no potency toward FGFR1/3 (IC50 = 140/130 nM), c-fms (IC50 = 146 nM), and other kinases tested (IC50 from >400 nM to >20 μM). Pazopanib exhibits anti-cancer efficacy in cultures (IC50 from 5 to 15 μg/mL; multiple myeloma migration and survival) and in mice in vivo (30-100 mg/kg/day p.o. against human MM xenografts) via angiogenesis inhibition and apoptosis induction.
基本信息
| 经验(实验)分子式 | C21H23N7O2S |
| 分子量 | 437.52 |
| MDL编号 | MFCD11616589 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 颜色 | white to beige |
| 溶解性 | DMSO: 2 mg/mL, clear (warmed) |
| 储存温度 | 2-8℃ |
| SMILES string | CN1N=C2C=C(N(C3=NC(NC4=CC=C(C(S(N)(=O)=O)=C4)C)=NC=C3)C)C=CC2=C1C |
| InChI | 1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25) |
| InChI key | CUIHSIWYWATEQL-UHFFFAOYSA-N |
安全信息
| 象形图 |   |
| 警示用语： | Danger |
| 危险声明 | H360FD - H373 - H411 |
| 预防措施声明 | P202 - P260 - P273 - P280 - P308 + P313 - P391 |
| 危险分类 | Aquatic Chronic 2 - Repr. 1B - STOT RE 2 |
| 靶器官 | Liver |
| 储存分类代码 | 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
m.cnreagent.com
